NCT03106077 - Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor NegativeFolate Receptor Alpha PositiveHER2/Neu NegativeProgesterone Receptor NegativePrognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Triple-Negative Breast Carcinoma

Interventions

BIOLOGICAL

Mirvetuximab Soravtansine

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER